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the time. Whereas 43% and 71% of husbands stated they
would be willing to give up >6mos of a 7-year survival
to avoid a 40% and 80% risk of impotence, respectively,
only 14% of wives would be willing for their husbands
to give up to 6mos of life to preserve potency at any level
of risk. For incontinence 14% and 29% of husbands vs.
0 and 14% of wives stated they would be willing to give
up, or have their husband give up, >6mos of a 7-year sur-
vival to avoid a 10% and 30% risk of incontinence,
respectively. When surgery, radiotherapy and watchful
waiting (WW) were presented with the same life ex-
pectancy but a 99% risk of impotence with the ﬁrst two
options and potency with the latter, 57% of husbands 
vs 14% of wives chose WW. When the same treatment
options were presented with the same life expectancy but
a 99% risk of incontinence with the ﬁrst 2 options and
urinary continence with the latter, 71% of husbands vs
14% of wives chose WW. CONCLUSION: Wives had a
higher utility than husbands for any treatment option vs.
WW, that prolongs the husbands life regardless of level
of risk of quality of life decrements. Wives’ preferences
were more congruent with observed (vs. stated) prefer-
ences of the husbands.
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OBJECTIVES: The National Cancer Institute established
the Cancer Outcomes Measurement Working Group
(COMWG) in 2001 to assess the state of the science of
cancer outcomes assessment and to identify areas requir-
ing further research to move the ﬁeld forward. During this
session, we will focus on COMWG ﬁndings related to
designing a patient-reported outcomes (PRO) measure-
ment strategy. METHODS: As part of the COMWG’s
mission, literature reviews of PRO studies in breast, col-
orectal, prostate, and lung cancer were conducted and the
performance of different measurement strategies (generic,
general cancer, cancer site-speciﬁc, unidimensional instru-
ments) were compared. Also, the role of modern psycho-
metric techniques was explored. RESULTS: In designing
a measurement strategy, there is often a trade-off between
comparability and sensitivity. The ability to compare 
and contrast ﬁndings across studies is enhanced when
more generic and widely-used instruments are employed.
However, using a speciﬁc instrument targeted to the 
particular dimensions hypothesized to differ between
groups can enhance sensitivity. Targeted unidimensional
measures were more effective at identifying differences
between groups than generic and general cancer mea-
sures. The importance of using targeted measures that
will be effective in identifying differences between groups
was felt by many COMWG investigators to outweigh the
potential usefulness of adopting a core set of measures 
to promote comparability, although, given sufﬁcient
resources, including both kinds of measures could be
useful. In the future, the use of modern psychometric
techniques, including item response theory, may render
moot the debate between sensitivity and comparability.
As item banks and computer-adaptive assessments are
developed, speciﬁc targeting of items can occur and,
because all items are calibrated using a common metric,
comparability can be promoted. CONCLUSIONS: In
designing a measurement strategy, the relative perfor-
mance of the different approaches requires consideration.
Modern psychometric techniques might contribute to
designing a measurement strategy that provides both 
sensitivity and comparability.
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OBJECTIVE: To examine the health-related quality of
life (HRQL) burden of head and neck cancer (HNC) and
HRQL issues related to its treatment. METHODS: A
computerized, systematic literature search was conducted
of the English-language literature published between
1990 and 2002. Augmenting the electronic identiﬁca-
tion of articles, manual searches were conducted of the
retrieved article bibliographies and appropriate confer-
ence proceedings (1999-2002). Type of study and 
analyses conducted, speciﬁc domains affected, factors
associated with short- and long-term HRQL, and impact
of treatment modality were examined. RESULTS: Of 851
abstracts screened, 97 articles met selection criteria and
were reviewed in detail. Forty-six were prospective, lon-
gitudinal studies; 51 were post-treatment studies with no
baseline data. Less than one-ﬁfth of the studies included
multivariate analysis. Before treatment, HNC patients
have poorer HRQL than age-matched controls in emo-
tional, physical, and social well-being. Impacts are greater
among younger age groups. Treatment especially affects
emotional, physical, and social well-being, pain, and
eating ability. Important predictors of HRQL include
speech and eating ability. Radiotherapy, chemotherapy
and surgery have acute, domain-speciﬁc impacts on
patient HRQL that are distinct from long-term impacts.
Emotional well-being remains unchanged or improves
with time, while eating ability worsens in the long-term.
Physical well-being worsens in the short-term with radio-
therapy/chemotherapy and in the long-term with surgery.
CONCLUSIONS: HNC and its treatment substantially
impact the HRQL of patients. Patients typically experi-
ence decreased HRQL during or shortly after treatment,
but then improved HRQL in the longer term. Future
studies should include multivariate analyses to control for
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clinical and demographic differences between patients,
and to better understand deﬁnitively the value of new
treatments.
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OBJECTIVE: The prevalence of brain metastases in
cancer patients is 20–40% and treatment options offer
median survivals of 4–10 months. Comparing two treat-
ments that do not offer increases in survival in a disease
state with a small survival rate lends itself to the study of
patient preferences. Patients are left to choose between
the risk of recurrent metastatic disease or the physical 
and cognitive side effects associated with treatment. The
objective of this study was to assess the feasibility of the
time trade-off method in patients with brain metastases
participating in a clinical trial. METHODS: An instru-
ment was developed for patients with brain metastases
undergoing radiosurgery with and without whole brain
radiation. Research nurses were trained to administer the
instrument face-to-face during clinic visits. RESULTS:
The instrument included a written script, data collection
form, and visual aid to facilitate the understanding of
trading time. Patients traded time for 3 different time
periods—10 years, 5 years, and one year. The piloted
instrument resulted in two changes: 1) the visual aid was
eliminated because it did not add to patients understand-
ing of trading time, and 2) the concept of “optimal
health” was used instead of “perfect health” because
patients had difﬁculty with the term. Currently, the
instrument has been administered to 25 patients. Fifty-six
percent, 44%, and 36% of patients traded time in the 10-
year, 5-year, and 1-year time period respectively. Three
patients from each time period increased the time that
they would trade during the course of treatment from
baseline. CONCLUSIONS: Methods used to elicit pref-
erences must be balanced with the practical issues of clin-
ical practice to yield clinically useful options to be used
by clinicians and patients for decision-making. 
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OBJECTIVE: Despite concerns associated with the 
necessity of an additional ﬂuorinated, high potency
topical corticosteroid, the clotrimazole/betamethasone
diproprionate combination remains a frequently pre-
scribed topical agent in the U.S. This research was per-
formed to better understand the circumstances in which
physicians across specialties in the U.S. recommend the
use of the combination medication in outpatient settings.
Additionally, the study aimed to determine the diagnoses
and characteristics of patients for whom the combination
medication was prescribed. METHODS: Data from the
National Ambulatory Medical Care Survey (1990-2000)
were used to determine the demographic characteristics
of patients with dermatologic diagnoses who were given
a prescription for clotrimazole/betamethasone dipropri-
onate. The most common diagnoses of patients treated
with the drug were also determined. RESULTS: Family
medicine physicians were more than twice as likely (OR:
2.61, 95% CI: 1.59, 4.30) and internists were more than
3 times as likely (OR: 3.52, 95% CI: 2.07, 5.97) 
to prescribe clotrimazole/betamethasone diproprionate
compared to all other physicians when faced with a der-
matologic diagnosis. Prescription rates of the combina-
tion medication were higher among patients of 
non-white race (OR: 1.55, CI: 1.07, 2.25). Contact 
dermatitis and other eczema ranked highest among 
diagnoses associated with the combination medication
mention by family medicine physicians, internists, and
pediatricians. CONCLUSIONS: The frequent use of
clotrimazole/betamethasone diproprionate by primary
care physicians is of concern. Use of alternative agents
with anti-inﬂammatory and antifungal properties without
the associated risks of high potency topical corticos-
teroids would be a preferable alternative.
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OBJECTIVES: Prostamides have recently been intro-
duced to treat glaucoma patients. We evaluated the effec-
tiveness and pharmacoeconomic impact of these newer
medications in treating patients with glaucoma. We com-
pared effectiveness and costs of bimatoprost monother-
apy versus latanoprost used with adjunctive therapies.
METHODS: A pharmacoeconomic model was con-
structed based on a two-month naturalistic effectiveness
trial comparing bimatoprost 0.03% (AWP of $53.13) in
patients switched from all possible combination therapies
with latanoprost 0.005% (AWP weighted total average
